VantroMarket Overview
← All markets
Health Market Overview

Portugal

Last updated: November 2026
Regulatory Body
INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.
Typical Timeline
30-210 days depending on product type and review procedure
Regulatory Overview

INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.) is the primary regulatory authority in Portugal responsible for overseeing the evaluation, authorization, and surveillance of medicinal products, medical devices, diagnostics, and cosmetics. Portugal operates within the European Union regulatory framework, meaning that pharmaceuticals may be approved via the EMA-led Centralized Procedure, the Decentralized Procedure, or the Mutual Recognition Procedure, in addition to purely national procedures. The main governing legislation includes Decree-Law No. 176/2006 (the Medicines Statute), Decree-Law No. 145/2009 for medical devices (now being superseded by EU MDR 2017/745 and EU IVDR 2017/746), and a growing body of EU-harmonized digital health regulation. For pharmaceuticals requiring national authorization, INFARMED conducts its own scientific review, while medical devices placed on the Portuguese market must bear CE marking in accordance with applicable EU regulations.

Submission dossiers for pharmaceutical marketing authorizations must conform to the Common Technical Document (CTD) format, aligned with ICH guidelines and EU Good Manufacturing Practice (GMP) standards. Applicants based outside the EU must appoint a locally established Marketing Authorization Holder (MAH) or European representative. For medical devices, manufacturers outside the EU are required to designate an Authorized Representative within an EU member state. Portugal has actively transposed the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), with INFARMED designated as the national competent authority for market surveillance. Recent reforms include enhanced post-market surveillance requirements, increased scrutiny of clinical evidence for higher-risk devices, and pilot frameworks for digital health and Software as a Medical Device (SaMD) assessment aligned with EU MDCG guidance. INFARMED also participates in the EU's Health Technology Assessment (HTA) joint clinical assessment process introduced under EU Regulation 2021/2282, which became applicable to oncology products and advanced therapy medicinal products from January 2025.

Procurement Overview

Public procurement of health products in Portugal is primarily coordinated through the Servico Nacional de Saude (SNS, the National Health Service), under the oversight of the Ministerio da Saude. Centralized procurement is conducted by SPMS (Servicos Partilhados do Ministerio da Saude, E.P.E.), the shared services entity responsible for national-level tenders for pharmaceuticals, medical devices, and diagnostics. SPMS negotiates framework agreements and public tenders under the Portuguese Public Procurement Code (Codigo dos Contratos Publicos, established by Decree-Law No. 18/2008 and subsequently revised), which transposes EU Directives 2014/24/EU and 2014/25/EU. Hospital-level and regional health administration (Administracoes Regionais de Saude, ARS) procurement may supplement centralized agreements, particularly for specialized or locally negotiated items. Pricing and reimbursement for pharmaceuticals are determined by INFARMED through a separate price-setting process involving international reference pricing benchmarked against a basket of EU member states.

Portugal does not rely significantly on multilateral donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, as it is a high-income EU member state with a well-established public health financing system. The private healthcare sector, including hospital groups such as Luz Saude and Jose de Mello Saude, procures independently through commercial channels and group purchasing arrangements, representing a meaningful parallel market for premium and innovative health products. There are no formal local manufacturing preference policies equivalent to those seen in emerging markets; however, Portugal has expressed strategic interest in strengthening European pharmaceutical supply chain resilience in alignment with the EU Pharmaceuticals Strategy and the Critical Medicines Act. Companies that participate in local clinical development, invest in in-country manufacturing partnerships, or contribute to SNS digital transformation initiatives may find favorable positioning during procurement negotiations and HTA engagement.

Go deeper

This is a generic market overview. For a structured entry brief tailored to your product category, including regulatory pathway, pricing, and risk assessment, use the Market Brief tool.

Generate a free Market Brief for Portugal →
Market overview generated by AI and updated monthly. Verify with in-country regulatory authorities before making market entry decisions.